Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $280.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective hoisted by Robert W. Baird from $252.00 to $280.00 in a research report report published on Tuesday morning, MarketBeat Ratings reports. They currently have an outperform rating on the specialty pharmaceutical company’s stock.

Several other brokerages have also recently issued reports on JAZZ. TD Cowen lifted their target price on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Truist Financial cut their price target on shares of Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Needham & Company LLC raised their price target on shares of Jazz Pharmaceuticals from $282.00 to $292.00 and gave the company a “buy” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft raised their price target on shares of Jazz Pharmaceuticals from $250.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Finally, Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $272.74.

Jazz Pharmaceuticals Trading Down 1.9%

NASDAQ JAZZ opened at $256.65 on Tuesday. Jazz Pharmaceuticals has a 12 month low of $106.65 and a 12 month high of $265.05. The company has a current ratio of 1.78, a quick ratio of 1.85 and a debt-to-equity ratio of 0.69. The stock’s fifty day moving average price is $240.89 and its 200-day moving average price is $209.19. The stock has a market cap of $16.66 billion, a P/E ratio of 17.70, a P/E/G ratio of 0.23 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.Jazz Pharmaceuticals’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($8.25) EPS. As a group, equities analysts forecast that Jazz Pharmaceuticals will post 21.61 EPS for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the sale, the director directly owned 360,682 shares of the company’s stock, valued at $91,245,332.36. This trade represents a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the transaction, the director owned 18,449 shares in the company, valued at $4,446,209. The trade was a 9.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 19,098 shares of company stock worth $4,649,786 in the last three months. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Capital World Investors raised its position in shares of Jazz Pharmaceuticals by 4.4% during the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock valued at $453,322,000 after buying an additional 111,735 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after acquiring an additional 191,637 shares during the last quarter. Franklin Resources Inc. grew its stake in Jazz Pharmaceuticals by 164.0% during the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after acquiring an additional 1,129,995 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after acquiring an additional 517,514 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. increased its holdings in Jazz Pharmaceuticals by 3.1% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,677,132 shares of the specialty pharmaceutical company’s stock valued at $285,113,000 after acquiring an additional 50,996 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo upgraded Jazz Pharmaceuticals to Buy and raised its price target to $300 from $285, adding to a broadly favorable analyst view. Jazz Pharmaceuticals Receives a Buy from Wells Fargo
• Positive Sentiment: Morgan Stanley raised its price target to $280, while Needham also forecast meaningful appreciation and maintained a bullish stance. JPMorgan separately indicated that the stock could rise, reinforcing investor confidence in JAZZ’s valuation and growth prospects. Morgan Stanley Boosts Jazz Pharmaceuticals Price Target
• Positive Sentiment: Jazz’s second-quarter revenue reached $1.21 billion, exceeding the $1.11 billion consensus estimate and increasing 15.5% year over year. Management raised its 2026 revenue guidance to $4.60 billion-$4.75 billion, supported by strength in its neuroscience and oncology businesses.
• Positive Sentiment: The Xywav-led oxybate franchise continues to post double-digit growth despite generic Xyrem competition, reducing concerns about near-term erosion in Jazz’s core business. Potential FDA approval of Ziihera for first-line gastroesophageal cancer on August 25 also provides an additional catalyst.
• Neutral Sentiment: A valuation comparison with Techne highlights JAZZ as a stock investors are assessing on earnings, growth and relative value metrics, but the article does not represent a new fundamental development for Jazz Pharmaceuticals. JAZZ vs. TECH Which Stock Is the Better Value Option
• Negative Sentiment: Adjusted quarterly EPS of $5.71 missed the $6.18 consensus estimate, which could limit upside if future earnings do not keep pace with revenue growth.
• Negative Sentiment: Director Bruce Cozadd sold 6,000 shares worth about $1.52 million under a pre-arranged Rule 10b5-1 plan. The sale reduced his holdings by only 1.64%, making it a limited signal of insider concern.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.